secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2022-05-11T23:59:59+00:00
Accession:  0001701541-22-000017
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Therapeutics Q1 net loss $25.5M; cash runway into Q3 2024; BDTX-1535 phase 1 dosed
--------------------------------------------------------------------------------

- Net loss $25.5M vs $30.3M Q1 2021; R&D expense $17.8M (down from $22.8M).
- Cash, equivalents, investments $179.7M; net cash used in ops $28.6M for Q1.
- First patient dosed April 2022 in Phase 1 for BDTX-1535 (EGFR inhibitor, GBM/NSCLC); clinical update in 2023.
- BDTX-4933 IND submission expected H1 2023; FGFR program candidate nomination in 2022.
- Reduced workforce ~30% in April 2022; cash runway extended into Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000170154122000017/0001701541-22-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000170154122000017/bdtx-20220511.htm
  HTML page:      https://secwatch.observer/filing/0001701541-22-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer